Edgewise Therapeutics, Inc. (EWTX) Stock Price, Financials & Summary

Price chart

Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21

Key dataOct 21, 2026

Open$39.95

From 52W high−17.99%

Volume1.83M

Market cap$4.31B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 21, 2026

Open

$39.95

From 52W high

−17.99%

Volume

1.83M

Market cap

$4.31B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−19.7x

P/E (TTM)

—

RSI (14)

50.5

MomentumView details →

1D Return

−0.25%

YTD Return

+61.74%

SummaryUpdated Jun 1, 2026

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Boulder, Colorado. The company went public in March 2021 and focuses on developing innovative small molecule therapies to treat rare musculoskeletal diseases. Edgewise specializes in precision medicine approaches targeting genetically defined muscle disorders, with their lead drug candidate currently in clinical development for treating devastating muscle-wasting diseases including Duchenne muscular dystrophy.

Ask drillr about Edgewise Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−19.7x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

9.6x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−44.02%

ROA (TTM)

−41.11%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−19.35%

FCF YoY

−27.02%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−12.41%

EBITDA YoY

−21.40%

MomentumView details →

1D Return

−0.25%

YTD Return

+61.74%

1Y Return

+169.60%

RSI (14)

50.5

vs 50D SMA

−4.42%

vs 200D SMA

+12.23%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

16.24x

Quick Ratio

16.24x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.53

EPS Surprise

−13.32%

Beats (12Q)

7/12

Next Q EPS Est

−$0.48

Avg Surprise (4Q)

−4.07%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−197.22M

Op. CF (TTM)

−159.42M

Next earningsNov 5, 2026 →

Latest newsMore news →

Edgewise Therapeutics dosed the first patient in its Phase 2 EQUINOX-HFpEF trial evaluating EDG-15400 in adults with symptomatic HFpEF and LVEF of at least 50%.13d ago

Edgewise Therapeutics unveiled the differentiated mechanism of action of its cardiac sarcomere modulator EDG-7500, which targets the Regulatory Light Chain and improved cardiac relaxation while preserving systolic function in preclinical models.29d ago

Similar companies

Dianthus Therapeutics, Inc.DNTH Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H02335.HK Jacobio Pharmaceuticals Group Co., Ltd.01167.HK Amicus Therapeutics, Inc.FOLD 丰倍生物603334.SH Tango Therapeutics, Inc.TNGX Find similar companies →

Latest newsMore news →

Edgewise Therapeutics dosed the first patient in its Phase 2 EQUINOX-HFpEF trial evaluating EDG-15400 in adults with symptomatic HFpEF and LVEF of at least 50%.13d ago Edgewise Therapeutics unveiled the differentiated mechanism of action of its cardiac sarcomere modulator EDG-7500, which targets the Regulatory Light Chain and improved cardiac relaxation while preserving systolic function in preclinical models.29d ago Edgewise Therapeutics reported a net loss of $57.3 million for Q2 2026, with R&D expenses of $47.5 million and G&A expenses of $14.4 million.77d ago